When CAR T-cell therapy relapses, several treatment options can be considered:

- Bispecific T-Cell Engagers (BiTEs): These involve antibodies that can bind to two antigens at once. The FDA approved teclistamab-cqyv (Tecvayli) for this purpose
- Monoclonal Antibodies: These are specialized antibodies that target specific read more

When CAR T-cell therapy relapses, several treatment options can be considered:

- Bispecific T-Cell Engagers (BiTEs): These involve antibodies that can bind to two antigens at once. The FDA approved teclistamab-cqyv (Tecvayli) for this purpose.
- Monoclonal Antibodies: These are specialized antibodies that target specific proteins on myeloma cells.
- Clinical Trials: These may offer access to novel treatments not yet FDA-approved or new combinations of existing drugs.

Always consult with your oncologist to determine the best course of action based on your specific situation.

 This AI-generated response comes from MyMyelomaTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

What Is the Relapse Rate for Multiple Myeloma? 9 Treatment Options After Relapse | MyMyelomaTeam

CAR-T Cell Therapy for Multiple Myeloma: What Is It? | MyMyelomaTeam